[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sheba Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,41,77,105,136,159,184,209,231,259,282,304,325,348,376,402,430,455,472,490,516,542,563,587,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643205","ex-vivo-drug-response-profiling-and-outcome-prediction-in-lung-adenocarcinoma-100643205",false,"NCT07636252","Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma","Inclusion Criteria:\n\n* Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.\n* Patient's written informed consent present.\n* Ability to understand the nature of the trial and the trial related procedures and to comply with them.\n\nExclusion Criteria:\n\n* negative cytology for malignancy in the last 6 months","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.",[24,25],"Lung Adenocarcinoma","Malignant Pleural Effusions (Mpe)",[27],"Drug sensitivity testing, malignant pleural effusion, lung cancer","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2023-06-14",{"date":36,"type":20},"2030-01-01",{"name":38,"class":39},"Sheba Medical Center","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":40},"100640034","sheba-healthspan-research-population-sharp-trial---sheba-longevity-center-diagnostic-and-intervention-protocol-to-lower-biological-age-in-older-adults-100640034","NCT07596576","Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults","Sheba Healthspan Research Population (SHARP) Trial","SHARP","Inclusion Criteria:\n\n* Healthy older adults \\>50 years old men and women\n\nExclusion Criteria:\n\n1. A former diagnostic of a significant cognitive reduction (MoCa score \\\u003C 24 ).\n2. Former diagnosis of neurodegenerative disease as Alzheimer's disease, Parkinson's disease, Lewy body dementia.\n3. Former diagnosis of psychiatric disease.\n4. In the past two years, underwent chemotherapy or radiation therapy.",true,"50 Years",{"count":52,"type":20},1500,"INTERVENTIONAL",[55],"NA","Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.\n\nWorking hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.\n\nMethods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (\\>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.\n\nExpected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.\n\nStudy importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.",[58,59,60,61,62],"Healthy Aging","Healthspan","Biological Age","Intrinsic Capacity","Immunaging",[64,65,66,67,68],"healthy longevity","healthspan","geromedicine","biological age","health trajectories","2026-05-18",{"date":71,"type":32},"2026-05-19",{"date":73,"type":32},"2024-03-01",{"date":75,"type":20},"2027-12-01",{"name":38,"class":39},{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":85,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":53,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":40},"100623814","phase-4-carbetocin-uterotonic-treatment-in-twin-pregnancies-for-prevention-of-postpartum-hemorrhage-100623814","NCT07401524","Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage","Carbetocin Administration for the Prevention of Postpartum Hemorrhage in Twin Deliveries: A Randomized Controlled Trial","CUTT-PPH","Inclusion Criteria:\n\n* Pregnant individuals aged ≥18 years\n* Twin pregnancies\n* Gestational age ≥23 weeks\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to carbetocin\n* Higher-order multiple gestation (triplets or more)\n* Maternal age \\\u003C18 years\n* Known placenta accreta spectrum\n* Known bleeding disorder\n* Intrauterine fetal death of one or more fetuses\n* Hyponatremia precluding oxytocin use\n* Planned delivery at a non-participating hospital","FEMALE",{"count":87,"type":20},120,[89],"PHASE4","The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.\n\nIn this study, bleeding will be evaluated by measuring how much blood hemoglobin levels drop from before delivery to the day after delivery.\n\nThe main questions this study aims to answer are:\n\n* Does giving carbetocin after delivery lower blood loss compared with standard oxytocin treatment?\n* Is carbetocin safe and practical to use in twin deliveries?\n\nResearchers will compare carbetocin to standard oxytocin treatment to see which approach better prevents bleeding after twin vaginal or cesarean delivery.\n\nParticipants will:\n\n* Be randomly assigned to receive either carbetocin or standard oxytocin after the second twin is delivered\n* Have blood tests before delivery and on the day after delivery\n* Be followed during their hospital stay and for up to six weeks after delivery for safety outcomes",[92,93],"Postpartum Hemorrhage","Twin Pregnancy",[95,96,97,92],"Carbetocin","Oxytocin","Twin Delivery","2026-05-05",{"date":100,"type":32},"2026-05-08",{"date":98,"type":32},{"date":103,"type":20},"2028-12-01",{"name":38,"class":39},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":49,"sex":85,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":53,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":40},"100624137","arm-position-and-blood-pressure-measurement-accuracy-during-pregnancy-100624137","NCT07405723","Arm Position and Blood Pressure Measurement Accuracy During Pregnancy","Arm Position and Blood Pressure Measurement Accuracy in Pregnancy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 18 to 55 years\n* Singleton or multiple viable intrauterine pregnancy\n* Gestational age corresponding to first, second, or third trimester at the time of enrollment\n* Ability to sit upright comfortably for the duration of blood pressure measurements\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Preexisting significant cardiac disease (e.g., arrhythmias, congenital heart disease, severe valvular disease)\n* Chronic kidney disease defined as serum creatinine ≥1.5 mg\u002FdL at enrollment\n* Significant upper limb or shoulder conditions that may affect arm positioning or blood pressure measurement (e.g., lymphedema, fractures, prior surgery, arteriovenous fistula)\n* Neurological or musculoskeletal conditions preventing proper positioning\n* Severe preeclampsia, eclampsia, or other acute medical conditions requiring immediate intervention\n* Major fetal anomaly\n* Intrauterine fetal demise","55 Years",{"count":114,"type":20},300,[55],"Accurate blood pressure measurement is essential during pregnancy, as blood pressure readings guide clinical decisions related to the diagnosis and management of hypertensive disorders of pregnancy. Clinical guidelines recommend measuring blood pressure with the arm supported at heart level; however, in routine practice, blood pressure is often measured with the arm in non-standard positions.\n\nThis study aims to evaluate how different arm positions affect blood pressure measurements in pregnant women. Pregnant women attending a high-risk pregnancy clinic will undergo blood pressure measurements with the arm placed in several commonly used positions, including supported at heart level, supported on the lap, and unsupported at the side. Each participant will have multiple measurements taken during a single clinic visit.\n\nThe study is designed as a randomized crossover trial with stratification by trimester and chronic hypertension status, allowing each participant to serve as her own control. Participants will be enrolled across all three trimesters of pregnancy, and results will be analyzed separately for each trimester. The primary outcome is the difference in systolic and diastolic blood pressure measurements between arm positions.\n\nThe findings of this study may help improve the accuracy of blood pressure measurement during pregnancy and inform clinical practice regarding optimal measurement techniques.",[118,119,120],"Pregnancy","Blood Pressure Measurement in Pregnancy","Hypertensive Disorder of Pregnancy",[122,118,123,124,125,126,127],"Blood Pressure Measurement","Arm Position","Hypertensive Disorders of Pregnancy","Prenatal Care","Blood Pressure Accuracy","Randomized Crossover Trial","2026-04-13",{"date":130,"type":32},"2026-04-16",{"date":132,"type":32},"2026-04-12",{"date":134,"type":20},"2026-12-31",{"name":38,"class":39},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":53,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100633183","facial-nerve-monitoring-during-parotid-and-facial-surgery-using-a-non-invasive-patch-100633183","NCT07523373","Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch","A Prospective Comparative Study Comparing Wireless Dry Electrode Patch and Standard EMG Monitoring for Intraoperative Facial Nerve Monitoring","Inclusion Criteria:\n\n* Age 18 to 99 years\n* Hebrew speakers\n* Ability to understand the study requirements and provide informed consent\n* Ability to cooperate with the research team throughout the study procedures\n\nExclusion Criteria:\n\n* Current or past comorbidity affecting facial nerve function\n* Previous injection of botulinum toxin to the face\n* Skin conditions that may interfere with the placement or function of the investigational patch, according to the manufacturer's guidelines\n* Known allergy to any component of the dry electrode patch","99 Years",{"count":145,"type":20},20,[55],"The goal of this study is to test if a non-invasive patch can safely monitor facial nerve activity in adults during parotid or facial surgery. Monitoring the facial nerve during these surgeries helps lower the risk of nerve injury and possible functional and aesthetic damage. Current methods use small needles and require careful placement, which can be difficult and may affect how well they work.\n\nThe aims to answer the following questions:\n\n* Can the patch provide similar results to the standard monitoring method?\n* Is the patch safe and easy to use during surgery?\n\nThe research team will compare the readings from the patch with those from the standard method used during surgery.\n\nParticipants will:\n\n* Undergo their planned surgery as usual\n* Have a patch placed on the face before the surgery\n* Have both the standard method and the patch monitor the facial nerve during surgery\n* Have the data extracted from the monitoring tools and analyzed without personal identifying information.\n\nAll the decisions during surgery will be based only on the standard method.",[149,150],"Parotid Gland Tumor","Facial and Neck Rhytides","NOT_YET_RECRUITING","2026-04-04",{"date":128,"type":32},{"date":155,"type":20},"2026-05-01",{"date":157,"type":20},"2028-02-18",{"name":38,"class":39},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":16,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":40},"100509075","closed-loop-medtronic-780g-system-in-youth-with-type-1-diabetes-100509075","NCT05908708","Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes","Title: Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes: AWeSoMe Study Group Prospective Trial","Inclusion Criteria:\n\nDiagnosis of type 1 diabetes Diabetes duration ≥ 6 months Routine attendance at clinic visits Initiation of 780G system usage\n\nExclusion Criteria:\n\nChildren under the age of 1 year Children without 780G system","1 Year","21 Years",{"count":87,"type":20},"The goal of this observational study is to describe data on Israeli children and youth using the 780G system including data regarding glycemic control parameters, various questionnaires, sleep data, bioimpedance measures, and dietary parameters. The main questions it aims to answer are: • whether the 780G system will improve glycemic control • whether the psychosocial aspects will improve. Participants will be followed once connected to 780G, at baseline, one, three, six months, 1 year, and two years after the connection.",[171,172],"Type 1 Diabetes","Child, Only",[174,175],"Technology","Insulin pump","2026-04-03",{"date":178,"type":32},"2026-04-09",{"date":180,"type":32},"2023-06-01",{"date":182,"type":20},"2026-07-01",{"name":38,"class":39},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":53,"phases":193,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":208,"locationsCount":40},"100632095","phase-1-9-cis-beta-carotene-rich-extract-of-dunaliella-alga-in-retinitis-pigmentosa-patients-100632095","NCT07509229","9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients","Treatment With 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients - a Randomized Crossover Double Masked Study","Inclusion Criteria:\n\n1. Written informed consent to participate in the study\n2. Men or women aged 18 years or older\n3. Electroretinogram (ERG) responses compatible with the diagnosis of retinitis pigmentosa\n4. Positive for mutation(s) in retinoid cycle related genes\n\nExclusion Criteria:\n\n1. Currently a smoker\n2. Current use of vitamin A\u002F β-carotene supplements\n3. Known mutations in the ABCA4 gene\n4. Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery\n5. History of malignancy, excepting basal or squamous cell skin carcinoma\n6. Women who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception\n7. Uncontrolled hypertension, defined either as resting diastolic blood pressure \\>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \\>180 mmHg\n8. History of alcohol abuse or drug abuse or both\n9. Intention to engage in vigorous exercise or an aggressive diet regimen\n10. Uncontrolled endocrine or metabolic disease\n11. Participation in another investigational drug study within 4 weeks prior to enrolment\n12. Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study\n13. Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment",{"count":192,"type":20},41,[194,195],"PHASE1","PHASE2","The goal of this clinical trial is to learn if a natural supplement called 9-cis beta-carotene (derived from the Dunaliella alga) can improve vision and retinal function in adults with Retinitis Pigmentosa. The study will also monitor the safety of the food supplement and how it affects levels of Vitamin A-related proteins in the blood. The main questions the study aims to answer are: (1) Does taking the supplement improve light sensitivity in the retina (measured by microperimetry)? (2) Does the supplement improve electrical responses in the eye (ERG) or other visual functions like contrast and color vision? (3) How do blood levels of beta-carotene and Vitamin A change during treatment? Researchers will use a crossover design. This means every participant will receive both the active supplement and a placebo (a \"dummy\" pill with corn oil) at different times during the study to compare the results. Participants will take two soft-gel capsules twice a day for 3 months, undergo a 6-month \"washout\" period where no study capsules are taken.Then they will take the opposite capsules (either the supplement or the placebo) for another 3 months. The participants will visit the clinic 4 times over the course of 12 months for eye exams, eye imaging (like OCT), and blood tests. Participants will also receive follow-up phone calls every 6 weeks to check on their progress and health.",[198],"Retinitis Pigmentosa",[200,201,202],"retinitis pigmentosa","retinoid cycle","beta carotene","2026-03-28",{"date":176,"type":32},{"date":155,"type":20},{"date":207,"type":20},"2029-04-30",{"name":38,"class":39},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":40},"100629462","portable-vr-based-chromatic-pupilloperimeter-for-diagnosis-and-monitoring-of-traumatic-brain-injury-100629462","NCT07474987","Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury","Development of a Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury","Inclusion Criteria:\n\n1. Male and female subjects\n2. Clear ocular media a\n\nTBI group:\n\n1. Combat-related mild to moderate TBI\n2. Have either elevated TBI-associated blood biomarkers (Abbott Allinity I, GFAP\u002F UCHL1) and\u002For initial trauma head CT positive for acute intracranial trauma\n\nNon-TBI Trauma group:\n\n1\\. Age- and gender-similar soldiers without TBI (defined as war-related injury who screen negative for TBI based on symptoms, blood, and\u002For head CT)\n\nExclusion Criteria:\n\n1. Neuropsychiatric diseases\n2. Any other neurodegenerative diseases\n3. History of stroke, epilepsy, head trauma, or head tumors\n4. Ocular disease or ocular surgery within the last six months","67 Years",{"count":218,"type":20},150,"Accurate and non-invasive methods for objectively identifying and monitoring head injuries (such as a concussion) are still an unmet need. It is known that pupil constriction in response to light stimuli can reflect changes in neural activity in the brain and is associated with sleep disturbances.\n\nThe investigators aim to examine the feasibility of using virtual reality goggles for monitoring traumatic brain injury by analyzing the pupillary response to multifocal chromatic stimuli. The VR device was programmed to present brief, low-intensity light stimuli (without glare), while the headset's camera records the pupil's reaction.",[221,222,223],"Traumatic Brain Injury (TBI) Patients","Healthy Participants","Non-TBI Trauma",{"date":225,"type":32},"2026-04-02",{"date":227,"type":20},"2026-04-01",{"date":229,"type":20},"2027-12-31",{"name":38,"class":39},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":16,"minAge":166,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":53,"phases":240,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":40},"100631643","phase-1-a-phase-12-study-of-t-cell-expressing-a-novel-cd19-chimeric-antigen-receptor-shb-02-cd19-in-patients-with-cd19-expressing-b-cell-malignancies-100631643","NCT07503353","A Phase 1\u002F2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies","Inclusion Criteria:\n\n* Patient must have a CD19-expressing hematologic malignancy, relapsed or refractory after receiving at least 2 lines of standard therapy and not eligible for current commercial CD19 CAR T cells per Israeli MOH health basket:\n\n  1. Relapse following standard relapse protocol (2nd relapse)\n  2. Primary refractory, i.e. failed to achieve morphologic remission after 2 lines of induction chemotherapy.\n  3. Patients who have histologically confirmed large B-cell lymphoma, according to the World Health Organization 2016 classification criteria, that are refractory to first-line treatment or that have relapsed from complete remission no more than 12 months after the completion of first-line chemo-immunotherapy including an anti-CD20 monoclonal antibody and anthracycline-containing regimen.\n  4. Very high risk 1st relapse of ALL, defined as (a) relapse within 18 months of initial diagnosis; (b) relapse with the following cytogenetic abnormalities: KMT2a-R, TCF3::HLF, TCF3::PBX1, TP53-alterations.\n* Age 1-80 years\n* For ALL, CD19 expression shown by flow cytometry or immunohistochemistry on at least 70% of leukemic blasts.\n* Adequate CD3 count (above 120 CD3+ cells per microliter blood)\n* Clinical performance status: Patients \\> 10 years of age: Karnofsky ≥ 50%; Patients ≤ 10 years of age: Lansky scale ≥ 50%. Exception for neurologic symptoms (e.g. paralysis) that are explained by the malignancy.\n* Females of child-bearing potential must have a negative pregnancy test\n* Cardiac function: LV ejection fraction \\>45% or shortening fraction \\>28%\n* At least 60 days after autologous or allogeneic BMT\n* No prior CD19 CAR T cell administered\n* Prior therapy:\n\n  1. Patients should be off steroids for at least 2 weeks prior to apheresis\n  2. Patients should be off systemic anti-neoplastic treatment for 2 weeks prior to apheresis, with the exception of intrathecal chemotherapy. Patients who received prior clofarabine and fludarabine should have a wash out period of 3 months prior to apheresis.\n  3. Patients should have recovered from all toxicities attributed to prior therapy. Cytopenias that are considered disease related rather than therapy related are exempt from this exclusion.\n  4. Radiation therapy should be completed at least 3 weeks prior to apheresis.\n\nExclusion Criteria:\n\n* Hyperleukocytosis (WBC\\>50,000) or rapidly progressive disease that in the judgment of the PI can compromise the ability of the patient to complete the study\n* Pregnant or breast-feeding females\n* Hepatic dysfunction, defined as bilirubin \\> x2 upper normal limit (except when explained by hemolysis or Gilbert) or SGOT \\> x2.5 upper normal limit.\n* Active HIV infection, HBV or HCV infection which is identified by positive PCR of viral sequences. Patients who are positive for HCV Abs, HBsAg and\u002For positive to HBcAbs total, will be evaluated by PCR of viral sequences. If PCR is positive, the patient will be excluded.","80 Years",{"count":239,"type":20},50,[194,195],"This is a phase I\u002FII trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed\u002Frefractory B-cell malignancies.",[243,244,245],"B Cell Malignancies","Acute Lymphobkastic Leukemia","Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)",[16,247,248,249,250],"DLBCL","NHL","CAR-T","CD-19","2026-03-25",{"date":253,"type":32},"2026-03-31",{"date":255,"type":20},"2026-06",{"date":257,"type":20},"2030-01",{"name":38,"class":39},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":53,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100629011","phase-2-group-vs-individual-mdma-assisted-therapy-for-ptsd-after-the-october-7-2023-events-100629011","NCT07469098","Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events","An Open-Label, Multicenter, Randomized, Non-Inferiority Study to Evaluate the Safety and Effectiveness of Group vs. Individual MDMA-Assisted Therapy in PTSD Patients Diagnosed Following the Events of October 7, 2023","Inclusion Criteria:\n\n1. Are at least 18 years old.\n2. At Screening, meet DSM-5 criteria for current PTSD that has been diagnosed past 7\u002F10\u002F23 and the events following.\n3. At Screening, have at least moderate PTSD symptoms in the last month, based on PCL-5 total score of 36 or greater, conducted by certified Study coordinators.\n4. Are fluent in speaking and reading the predominantly used or recognized language of the study site (Hebrew).\n5. Are able to swallow pills.\n6. Participant where in psychotherapy prior to the study. If the participant is still in psychotherapy during study enrollment, they consent to continue therapy during the study and provide consent for the investigator to communicate with the therapist as needed.\n7. Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n8. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.\n9. Agree to the following lifestyle modifications (see lifestyle modifications section) : comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not participate in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.\n10. If able to become pregnant (i.e. assigned female at birth, fertile, following menarche and until becoming post-menopausal unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate birth control through 10 days after the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).\n11. Holds a permanent address in the next 6 months.\n\nMedical History\n\n1. May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines, if they pass additional screening to rule out underlying cardiovascular disease.\n2. May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.\n3. May have alcohol or substance use disorder if the participant is not in withdrawal or requiring detox. Participants must have a plan, agreed upon by the investigator, therapy team, and study physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the investigator, therapy team, and study physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or efficacy of the investigational treatment.\n4. May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the study physician.\n5. May have hypothyroidism if taking adequate and stable thyroid replacement medication.\n6. May have a history of, or current, glaucoma if approval for study participation is received from an ophthalmologist.\n\nExclusion Criteria:\n\n1. Are not able to give adequate informed consent.\n2. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or study clinician, contraindicates participation in the study.\n3. Active military duty expected in the following 12 months.\n4. Death of a close person in the past 6 months.\n\nPsychiatric History\n\n1. Have received Electroconvulsive Therapy, Transcranial Magnetic Stimulation, or Ketamine Therapy within 12 weeks of enrollment.\n2. Have a history of, or a current diagnosis of schizophrenia, schizoaffective disorder, major depressive disorder with psychotic features, psychotic disorder, bipolar disorder I or II (with or without psychotic features), or dissociative identity disorder assessed by medical history, investigator interview and the Mini-International Neuropsychiatric Interview (MINI).\n3. Have a current substance use disorder other than caffeine or nicotine that the investigators, therapy team, and\u002For study physician judge to be a safety concern for enrollment in the study or that could interfere with the therapeutic process or with other aspects of study participation as assessed by clinical interview per DSM-5 as well as Audit and Dudit questionnaires. Any participant who is not able to agree or adhere to a plan to reduce use and manage symptoms will not be enrolled.\n4. Have an active illicit (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment.\n5. Have current Personality Disorders Cluster A (paranoid, schizoid, schizotypal), Cluster B (antisocial, borderline, histrionic, narcissistic), or Cluster C (avoidant, dependent, obsessive-compulsive) assessed via SCID-5-PD.\n6. Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the Baseline C-SSRS will be excluded:\n\n   1. Suicidal ideation score of 4 or greater within the last 6 months of the assessment at a frequency of once a week or more.\n   2. Suicidal ideation score of 5 within the last 6 months of the assessment.\n   3. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. Participants with non-suicidal self-injurious behavior may be included if approved by the study physician.\n7. Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist.\n8. Have a blood or needle phobia that interferes with obtaining necessary blood work.\n9. Have an immediate family member diagnosed with a psychotic disorder to the participant's knowledge.\n\nMedical History\n\n1. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm. Participants with other mild, stable chronic medical problems may be enrolled if the study physician and sponsor-investigator agree the condition would not significantly increase the risk of MDMA administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the use of MDMA. Examples of stable medical conditions that could be allowed include, but are not limited to Diabetes Mellitus (Type 2), Human Immunodeficiency Virus (HIV) infection, Gastroesophageal Reflux Disease (GERD), etc. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism would require exclusion.\n2. Have uncontrolled essential hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions).\n3. Have a history of ventricular arrhythmia at any time, other than premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n4. Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n5. Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs and confirmed by a cardiologist.\n6. Have a marked Baseline prolongation of QT\u002FQTc interval e.g., repeated demonstration of a QTc interval \\> 450 milliseconds (ms) in males and \\>460 ms in females corrected using Fridericia's formula. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for 5 or more years.\n7. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n8. Require use of concomitant medications that prolong the QT\u002FQTc interval during Experimental Sessions. Refer to protocol section on Concomitant Medications.\n9. Have symptomatic liver disease or have significant liver enzyme elevations.\n10. Have history of hyponatremia or hyperthermia.\n11. Weigh less than 48 kilograms (kg).\n12. Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment.","75 Years",{"count":268,"type":20},168,[195],"The goal of this clinical trial is to evaluate the safety, tolerability and effectiveness of group-based MDMA-assisted therapy compared to individual MDMA-assisted therapy in participants with PTSD, who were diagnosed following the events of 7 October 2023. The main questions it aims to answer are: safety and tolerability? effectiveness? Researchers will compare group-based MDMA-assisted therapy to individual MDMA-assisted therapy to see if group-based MDMA-assisted therapy is not inferior to individual MDMA-assisted therapy, in terms of safety and effectiveness.\n\nParticipants will be randomized to one of two study arms: group-based MDMA-assisted therapy or individual MDMA-assisted therapy receive MDMA HCl administered orally in a divided dose. Participate in preparatory sessions, MDMA dosing sessions, and integration sessions. Be monitored for adverse events and suicidality (C-SSRS). Be monitored by an external Data Safety Monitoring Board (DSMB).",[272],"PTSD","2026-03-09",{"date":275,"type":32},"2026-03-13",{"date":277,"type":32},"2025-12-24",{"date":279,"type":20},"2029-03-31",{"name":38,"class":39},2,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":40},"100623678","mitochondrial-function-after-ketamine-100623678","NCT07399756","Mitochondrial Function After Ketamine","Assessment of Mitochondrial Parameters in Blood Before and After S-Ketamine Treatment","Inclusion Criteria:\n\nMale or female, 18-65 years of age Diagnosis of Major Depressive Disorder according to the DSM-V Patient has a HAM-D≥23 Treatment resistant -Did not respond to two antidepressants trial Medically stable: No active physical disease: malignancy, cardiac condition, hypertension , stable medications for the past month etc.\n\nExclusion Criteria:\n\nKnown sensitivity to ketamine drug or alcohol abuse Patient taking lithium or corticosteroids Pregnant or breast-feeding has another axis I diagnosis attention deficits disorder a history or current serious neurological, metabolic autoimmune bone marrow, oncologic or additional psychiatric disorders",{"count":290,"type":20},30,"The goal of this observational study is to learn about the role of mitochondria in response to S-ketamine. in individuals with Treatment-Resistant Depression.\n\nthe Research Questions are\n\n1. Does S-ketamine treatment modulate mitochondrial function in peripheral blood cells, as reflected by mitochondrial content and circulating mitochondrial biomarkers such as GDF15?\n2. Can changes in mitochondrial function serve as biomarkers for predicting or monitoring clinical response to S-ketamine treatment?\n\nSamples will be collected at baseline, 3 hours after the first treatment, and 6 weeks post-exposure, and compared between responders and non-responders",[293],"Major Depressive Disorder",[295],"ketamine, Mitochondrial, Treatment-Resistant Depression","2026-02-03",{"date":298,"type":32},"2026-02-10",{"date":300,"type":20},"2026-02",{"date":302,"type":20},"2028-01",{"name":38,"class":39},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":311,"targetDuration":313,"studyType":21,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":40},"100602036","oral-health-saliva-viscosity-and-composition-in-oculo-pharyngeal-muscular-dystrophy-opmd-100602036","NCT07118280","Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)","Saliva Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)","Inclusion Criteria:\n\n* Patients with OPMD and their spouses or household members\n\nExclusion Criteria:\n\n* • Pregnancy or presence of any disease that may affect a composition of saliva",{"count":312,"type":20},100,"1 Day","The goal of this observational study is to explore whether oral health and saliva viscosity and composition in Oculopharyngeal Muscular Dystrophy (OPMD) is different from control subjects.\n\nThe main questions it aims to answer are:\n\nDo swallowing disturbances in OPMD adversely affect oral health? Is saliva thickness (viscosity) is increased in OPMD? Does saliva in OPMD contains biochemical markers of the disease?",[316],"Oculopharyngeal Muscular Dystrophy","2026-01-25",{"date":319,"type":32},"2026-01-27",{"date":321,"type":32},"2023-03-01",{"date":323,"type":20},"2027-03",{"name":38,"class":39},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":16,"minAge":166,"maxAge":237,"enrollmentInfo":331,"targetDuration":4,"studyType":53,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":40},"100603357","phase-1-a-phase-12-study-of-t-cell-expressing-an-anti-cd22-chimeric-antigen-receptor-shb-04-cd22-in-patients-with-cd22-expressing-b-cell-malignancies-100603357","NCT07135466","A Phase 1\u002F2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies","Inclusion Criteria:\n\n* Patient must have a CD22-expressing hematologic malignancy, relapsed or refractory after receiving at least 2 lines of standard therapy including CD19-directed therapy (For CD19 positive disease):\n* Relapse following standard relapse protocol (2nd relapse), including CD19 CART.\n* Primary refractory, i.e. failed to achieve morphologic remission after 2 lines of induction chemotherapy.\n* Age 1-80 years\n* CD22 expression shown by flow cytometry on at least 70% of leukemic blasts \u002F lymphoma cells\n* Adequate CD3 count (above 120 CD3+ cells per microliter blood)\n* Clinical performance status: Patients \\> 10 years of age: Karnofsky ≥ 50%; Patients ≤ 10 years of age: Lansky scale ≥ 50%. Exception for neurologic symptoms (e.g. paralysis) that are explained by the malignancy.\n* Females of child-bearing potential must have a negative pregnancy test\n* Cardiac function: LV ejection fraction \\>45% or shortening fraction \\>28%\n* At least 60 days after autologous or allogeneic BMT\n* At least 30 days after prior CAR therapy in absence of response",{"count":239,"type":20},[194,195],"This is a phase I\u002FII trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed\u002Frefractory B-cell malignancies.",[243],[16,248,247,249,336,337,338,339],"CD22","Chimeric Antigen Receptor","Leukemia","Lymphoma","2026-01-14",{"date":342,"type":32},"2026-01-16",{"date":344,"type":20},"2026-02-01",{"date":346,"type":20},"2028-01-01",{"name":38,"class":39},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":53,"phases":357,"briefSummary":358,"conditions":359,"keywords":363,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100616696","phase-4-comparison-of-the-efficacy-and-safety-of-4-vs-8-treatments-with-tepezza-teprotumumab-for-thyroid-eye-disease-100616696","NCT07308964","Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease","A Comparative Study of Shortened (4-Infusion) Versus Standard (8-Infusion) Teprotumumab Regimens in Patients With Thyroid Eye Disease (TED) Exhibiting an Early Optimal Clinical Response","Inclusion Criteria:\n\n* Participants must have a confirmed diagnosis of active Thyroid Eye Disease (TED).\n* Participants must be eligible for and have started the standard Teprotumumab (Tepezza) treatment protocol.\n* Participants must demonstrate a significant clinical response by the 4th infusion.\n* Ability to understand and provide signed written informed consent.\n\nExclusion Criteria:\n\n* Previous use of Teprotumumab or other biologic therapies for TED.\n* Participants who do not show early clinical response after the 4th infusion.\n* Participants who have any medical contraindications to Teprotumumab or any of its components.\n* Participants who have any known hearing problems.",{"count":356,"type":20},40,[89],"The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).\n\nThe main question it aims to answer is:\n\n\\* Is a shorter course equally effective and safe for patients who respond well early in treatment.\n\nParticipants who demonstrate an early clinical response as part of their treatment with Teprotumumab will receive a shorter protocol of 4 infusions instead of the standard 8.",[360,361,362],"Thyroid Eye Disease","Thyroid Eye Disease, TED","Thyroid Eye Disease (TED)",[364,365,366,367],"thyroid eye disease","TED","Tepezza","Teprotumumab","2025-12-28",{"date":370,"type":32},"2025-12-30",{"date":372,"type":20},"2026-01",{"date":374,"type":20},"2028-05",{"name":38,"class":39},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":85,"minAge":17,"maxAge":50,"enrollmentInfo":383,"targetDuration":4,"studyType":53,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":40},"100607046","phase-4-azithromycin-and-ampicillin-for-late-pprom-100607046","NCT07183462","Azithromycin and Ampicillin for Late PPROM","ALPRO","Inclusion Criteria:\n\n* Maternal age 18-50\n* Premature rupture of membranes\n* Gestational age 34.0 and 36.4 weeks\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Multiple gestations\n* Individuals in active labor (defined as 3 cm dilatation and 80% effacement or more. or regular uterine construction of more than 4 in 10 minutes)\n* Meconium stain amniotic fluid\n* Non-reassuring fetal heart rate or status\n* Maternal or fetal indication for labor:\n\n  * Suspected Chorioamnionitis\n  * Suspected placental abruption\n  * Any maternal morbidity requiring labor\n* Cervical cerclage in place.\n* Major fetal malformation or known chromosomal abnormalities.\n* Stillbirth.\n* Sensitivity to Macrolides Antibiotics",{"count":384,"type":20},311,[89],"The goal of this clinical trial is to learn whether adding azithromycin to the standard antibiotic treatment (ampicillin) improves newborn outcomes in women with preterm premature rupture of membranes (PPROM) between 34.0 and 36.6 weeks of pregnancy.\n\nThe main question it aims to answer is:\n\nDoes the combination of ampicillin and azithromycin lower the risk of serious neonatal health problems compared to ampicillin alone?\n\nResearchers will compare two antibiotic regimens:\n\nAmpicillin alone, which is the current standard care Ampicillin with azithromycin, a broader regimen that may better prevent infections and prolong pregnancy\n\nParticipants will:\n\nReceive one of the two antibiotic treatments during hospitalization. Be monitored until delivery for signs of infection and labor\n\nAll participants will stay in the hospital until delivery. The study also looks at how the antibiotic choice may affect the time between membrane rupture and delivery, maternal infections, and the need for neonatal intensive care.",[388,389,390,391,392,393],"Pregnancy Complications, Infectious","Premature Birth","Neonatal Diseases and Abnormalities","Antibiotic Prophylaxis","Latency Period","Prematurity","2025-12-10",{"date":396,"type":32},"2025-12-18",{"date":398,"type":32},"2025-09-10",{"date":400,"type":20},"2029-07-31",{"name":38,"class":39},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":53,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":40},"100610197","liquid-biopsy-following-bbb-disruption-using-barrier-disrupting-fields-in-patients-undergoing-spine-surgery-100610197","NCT07224451","Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery","Liquid Biopsy Following Blood-Brain Barrier Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery","BDF002","Inclusion Criteria:\n\n* Adult subjects over the age of 18\n* Able to sign informed consent\n* Candidates for intradural tumor resection spinal surgery with intraoperative neuromonitoring.\n\nExclusion Criteria:\n\n* Pacemakers, or other implanted electric medical devices\n* Pregnant or lactating females\n* Major medical, neurologic or psychiatric condition who are judged as unable to fully comply with the study\n* History of skull fractures or previous brain surgery\n* American Society of Anesthesiologists grade \\>2\n* Anticoagulants treatment\n* Damage to the dura resulting in CSF leak\n* Patients with seizures\u002Fepilepsy",{"count":145,"type":20},[55],"Objective: To identify new central nervous system (CNS) biomarkers to be used for blood-derived liquid biopsy once the blood-brain barrier (BBB), specifically the blood-arachnoid barrier (BAB), has been transiently disrupted by BDF in patients undergoing spine surgery.\n\nDesign: Single center (Sheba Medical Center), prospective, controlled. Phase: Feasibility study\n\nEndpoints:\n\nEfficacy The primary endpoint of the study is the elevation in blood concentration of CNS biomarkers following the study procedure compared to biomarkers detected in cerebrospinal fluid (CSF) of the same subject.\n\nSafety The primary safety endpoint will be the overall incidence of BDF procedure-related AEs and SAEs, with severity graded according to CTCAE v5.0 criteria.\n\nStudy population:\n\nThe study population will include up to 20 patients undergoing spine surgery.\n\nStudy period:\n\n24 months.\n\nInclusion criteria:\n\n1. Adult subjects over the age of 18\n2. Able to sign informed consent\n3. Candidates for intradural tumor resection spinal surgery with intraoperative neuromonitoring.\n\nExclusion criteria:\n\n1. Pacemakers, or other implanted electric medical devices\n2. Pregnant or lactating females\n3. Major medical, neurologic or psychiatric condition who are judged as unable to fully comply with the study\n4. History of skull fractures or previous brain surgery\n5. American Society of Anesthesiologists grade \\>2\n6. Anticoagulants treatment\n7. Damage to the dura resulting in CSF leak\n8. Patients with seizures\u002Fepilepsy\n\nStudy procedure:\n\n1. Candidates for intradural tumor resection spinal surgery with intraoperative neuromonitoring will be enrolled in the study prior to surgery.\n2. The patient will undergo preparation for surgery according to the standard care.\n3. Once anesthetized and intubated, electrodes will be attached to the patient's head.\n4. After placing the electrodes, when the patient is under anesthesia, a blood sample will be taken prior to BDF. This sample will be used as baseline for BDF.\n5. The patient will then undergo a BDF procedure.\n6. Additional blood samples will be taken for identification of CNS biomarkers.\n7. Surgery will then proceed according to the standard of care.\n8. Once the dura is opened, a CSF sample will be taken, in order to compare the blood biomarkers of the specific subject with the CSF biomarkers.\n9. The surgery will continue according to the standard of care.",[414],"Spinal Tumors",[416,417,418,419,420,421],"Barrier disrupting fields","pulse electrical fields","blood-brain barrier opening","blood-arachnoid barrier opening","liquid biopsy","spinal tumors","2025-11-03",{"date":424,"type":32},"2025-11-04",{"date":426,"type":32},"2025-10-16",{"date":428,"type":20},"2027-10",{"name":38,"class":39},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":437,"targetDuration":4,"studyType":53,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":454,"locationsCount":40},"100309129","multifocal-chromatic-pupilloperimetry-in-patients-with-pseudotumor-cerebri-and-healthy-subjects-100309129","NCT03304314","Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects.","Assessment of Pupillary Response and Visual Field Defects by Objective Multifocal Chromatic Pupillometer in Patients With Pseudotumor Cerebri and Healthy Subjects","Inclusion Criteria:\n\nHealthy subjects\n\n1. Male or female patients, age between 18 and 80 years, inclusive\n2. Informed written consent will be obtained from all participants.\n3. Normal eye examination\n4. Best-corrected visual acuity (BCVA) of 20\u002F20\n5. Normal color vision test (Ishihara\u002FHRR)\n6. Normal Spectral-Domain Optical Coherence Tomography (SD-OCT)\n7. Normal 24-2 Humphrey visual field (SITA Standard) and:\n\n   * Short duration (≤10 minutes)\n   * Minimal fixation losses, False POS errors and False NEG errors (less than 33% for each one of reliability indices)\n\nPTC patients\n\n1. Male or female patients, age between 18 and 80 years, inclusive\n2. Best-corrected visual acuity (BCVA) of at least 20\u002F100 in worse eye\n3. Optic disc edema\n4. PTC diagnosis based on Modified Dandy Criteria ( lumbar puncture with opening pressure higher than or equal to 25 cm H2O, normal cerebrospinal fluid constituents, and unremarkable brain imaging results except typical for PTC\n\nExclusion Criteria:\n\nHealthy subjects\n\n1. History of past (last 3 months) or present ocular disease or ocular surgery\n2. Use of any topical or systemic medications that could adversely influence pupillary reflex\n3. Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tonometry or other schedule study procedure.\n4. Mental impairment or instability such as that informed consent may not be obtained or compliance with tester instructions is unlikely.\n5. Visual media opacity including cloudy corneas.\n6. Any condition preventing accurate measurement or examination of the pupil.\n\nPTC patients\n\n1. Any other neurologic or ophthalmic disease other than PTC\n2. Use of any topical or systemic medications that could adversely influence pupillary reflex\n3. Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tonometry or other schedule study procedure.\n4. Mental impairment or instability such as that informed consent may not be obtained or compliance with tester instructions is unlikely.\n5. Visual media opacity including cloudy corneas.\n6. Any condition preventing accurate measurement or examination of the pupil.",{"count":312,"type":20},[55],"PTC(Pseudotumor cerebri) patients may develop increased Intracranial pressure (ICP) that can produces increased pressure around the distal optic nerve,which is likely followed by venule compression, ischemia, and loss of visual function.Vision loss in PTC is most commonly characterized by standard automated perimetry to measure peripheral visual field sensitivity.\n\nPupillometry is a promising approach for functional assessment in PTC because it is noninvasive, objective, performed quickly with minimal patient cooperation needed.\n\nThe feasibility of using chromatic multifocal pupillometry for assesment of PTC will be examined.",[441],"Pseudotumor Cerebri",[443,444,445,446,447],"PTC","EYES","Pseudotumor cerebri","increased Intracranial pressure","ICP","2025-09-30",{"date":450,"type":32},"2025-10-06",{"date":452,"type":32},"2017-11-03",{"date":229,"type":20},{"name":38,"class":39},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":462,"enrollmentInfo":463,"targetDuration":313,"studyType":21,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":471,"locationsCount":40},"100210952","determination-of-physical-parameters-relevant-to-ophthalmic-lasers-100210952","NCT02023073","Determination of Physical Parameters Relevant to Ophthalmic Lasers","Study of Physical Parameters Related to Laser Radiation and Its Interaction With Different Parts of the Human Eye","Inclusion Criteria:\n\n* Age 18-40 years\n* Refraction up to ±0.25D,\n* General good health\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* known current ophthalmic pathology\n* known past ophthalmic pathology (including LASIK surgery)\n* eye glasses or contact lenses","40 Years",{"count":145,"type":20},"The use of lasers in medicine in general, and diagnosis and treatment in ophthalmology in particular, increased significantly. Making retinal surgery using lasers have become increasingly common. The goal: to diagnose eye diseases safely",[466],"Healthy Volunteers",{"date":450,"type":32},{"date":469,"type":32},"2018-07-01",{"date":229,"type":20},{"name":38,"class":39},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":16,"minAge":479,"maxAge":17,"enrollmentInfo":480,"targetDuration":4,"studyType":53,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":40},"100210617","phase-1-the-effect-of-oral-administration-of-9-cis-rich-powder-of-the-alga-dunaliella-bardawil-on-visual-functions-in-adolescent-patients-with-retinitis-pigmentosa-100210617","NCT02018692","The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa","The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa","Inclusion Criteria:\n\n* Written informed consent to participate in the study.\n* Adolescent 12-18 years old.\n* Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa\n\nExclusion Criteria:\n\n* Currently a smoker\n* Current use of vitamin A\u002F β-carotene supplements\n* Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery\n* History of malignancy, excepting basal or squamous cell skin carcinoma\n* Females who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception\n* Uncontrolled hypertension, defined either as resting diastolic blood pressure \\>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \\>180 mmHg\n* History of alcohol abuse or drug abuse or both\n* Intention to engage in vigorous exercise or an aggressive diet regimen\n* Uncontrolled endocrine or metabolic disease\n* Participation in another investigational drug study within 4 weeks prior to enrolment\n* Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study\n* Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment","12 Years",{"count":290,"type":20},[194,195],"The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.",[198],{"date":450,"type":32},{"date":486,"type":20},"2026-03-01",{"date":488,"type":20},"2028-12-31",{"name":38,"class":39},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":497,"targetDuration":498,"studyType":21,"phases":4,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":515,"locationsCount":40},"100604187","natural-history-of-oculo-pharyngeal-muscular-dystrophy-opmd---israel-national-opmd-registry-100604187","NCT07146256","Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry","Isr-OPMD","Inclusion Criteria:\n\n* Patients with clinical diagnosis of OPMD or patients with signs \u002Fsymptoms suggestive of OPMD\n\nExclusion Criteria:\n\n* Age \\\u003C18 years and Pregnancy",{"count":114,"type":20},"5 Years","The goal of this open prospective multi-disciplinary observational study of patients with OPMD at various stages of clinical manifestations is to explore the natural history of the disease in the Israeli population.",[501],"Oculopharyngeal Muscular Dystrophy (OPMD)",[503,504,505,506,507,508],"Oculopharyngeal muscular dystrophy (OPMD)","Natural history","Dysphagia","Eyelid ptosis","Muscle weakness","Oral health","2025-08-21",{"date":511,"type":32},"2025-08-28",{"date":513,"type":32},"2022-02-01",{"date":257,"type":20},{"name":38,"class":39},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":541,"locationsCount":40},"100603026","real-world-stage-ii-iii-nsclc-patients-receiving-neoadjuvant-chemo-immunotherapy-and-no-surgical-resection-100603026","NCT07131163","Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection","Neoadjuvant Chemo-immunotherapy Not Resected","NoSurgery","Inclusion Criteria:\n\n1. Stage II-III NSCLC patient, based on clinical staging.\n2. Treated by a chemo-immunotherapy regimen defined as neoadjuvant treatment, for at least one cycle of treatment.\n3. No surgery was performed for at least six months from initiation of the neoadjuvant treatment.\n4. availability of data about reasons for surgery cancellation and clinical follow up.\n5. patient's consent for data collection (or waiver of the need for consent by the local ethics committee)\n6. At least 6 month of follow up after intiation of neoadjuvant treatment.",{"count":525,"type":20},60,"Neoadjuvant chemo-immunotherapy, with or without adjuvant immunotherapy, is currently the standard of care for resectable stage II-III NSCLC. One of the major drawbacks of neoadjuvant treatment is the risk of surgery cancellation. In most of the studies including a neoadjuvant component of treatment, about 20% of recruited patients do not undergo surgery. The reasons for surgery cancellation are recorded as a mixture of adverse events, disease progression, patient's decision and physician's decision. There is lack of data about the precise reasons for cancellation of the surgery. For patients starting neoadjuvant chemo-immunotherapy followed be cancellation of surgery, there is lack of data about the need to add additional treatments and about outcome of these treatments. Depending on the reason for surgery cancellation, these patients might undergo salvage radiotherapy (or chemo-radiotherapy), switch to systemic treatment as for metastatic disease or to palliative care.\n\nGoal of the study: to collect real-world data about NSCLC patients that started neoadjuvant chemo-immunotherapy and did not get to surgery.\n\nStudy conduct Participating centers will secure approvals for retrospective collection of clinical data. Relevant patients will be identified from the working database of each center, data will be collected locally, deidentified and collected centrally at the Sheba MC.\n\nData collected will include: demographics (age, sex); patients' characteristics (smoking status, co-morbidities, ECOG-PS, weight loss); tumor characteristics (histology, molecular tests, specific test results, clinical stage); staging procedures done (CT, PET-CT, brain MRI, EBUS, mediastinoscopy); neoadjuvant treatment (regimen, number of cycles, dose reductions, delays); reason for surgery cancellation; to be categorized according to the following options: iRAE\u002F non-immune-related AEs\u002F molecular test results\u002F re-staging result showing lack of mediastinal clearing\u002F distant disease progression\u002F local progression leading to patient becoming not-resectable\u002F re-assessment of patient as not-resectable (without a significant change in the tumor)\u002F change in the patient condition making the patient not-operable.\n\nMajor Inclusion criteria:\n\n1. Stage II-III NSCLC patient, based on clinical staging.\n2. Treated by a chemo-immunotherapy regimen defined as neoadjuvant treatment, for at least one cycle of treatment.\n3. No surgery was performed for at least six months from initiation of the neoadjuvant treatment.",[528],"Stage II-III Non-small Cell Lung Cancer",[530,531,532,533,534],"neoadjuvant","NSCLC","Non-small-cell lung cancer","immunotherapy","chemotherapy","2025-08-12",{"date":537,"type":32},"2025-08-20",{"date":539,"type":32},"2024-07-16",{"date":370,"type":20},{"name":38,"class":39},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":53,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":4},"100597399","trans-cervical-and-trans-abdominal-ultrasound-for-monitoring-esophageal-thickness-in-eosinophilic-esophagitis-100597399","NCT07057986","Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis","Inclusion Criteria:\n\n* Age ≥18 years.\n* Suspected or confirmed diagnosis of EoE based on clinical symptoms (e.g., dysphagia, food impaction).\n* Scheduled for upper endoscopy with biopsies.\n* Able and willing to consent to participation.\n\nExclusion Criteria:\n\n* Prior esophageal surgery or anatomical abnormalities.\n* Presence of other gastrointestinal disorders affecting the esophagus (e.g., esophageal cancer, achalasia, Barrett's esophagus).\n* Pregnancy.\n* Inability to undergo US due to anatomical or physical limitations.",{"count":312,"type":20},[55],"Eosinophilic Esophagitis (EoE) is a chronic inflammatory disease characterized by eosinophilic infiltration of the esophageal mucosa, leading to symptoms of dysphagia and food impaction. Currently, upper endoscopy with biopsy is the gold standard for diagnosis and disease monitoring, but it is invasive, costly, and associated with procedural risks. The investigators want to use ultrasound imaging as a non-invasive assessment of esophageal wall thickness as a surrogate marker for mucosal inflammation.\n\nParticipants will undergo ultrasound assessment at the same day of endoscopy, and than after 3-6 months (optional). The correlation between US-measured esophageal thickness and histological eosinophil counts will be measured.",[552],"Eosinophilic Esophagitis (EoE)",[554],"eosinophilic esophagitis","2025-07-24",{"date":557,"type":32},"2025-07-29",{"date":559,"type":20},"2025-08-01",{"date":561,"type":20},"2028-08-01",{"name":38,"class":39},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":53,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":40},"100509145","phase-2-crizanlizumab-alone-or-in-combination-with-nivolumab-for-glioblastoma-and-melanoma-with-brain-metastases-100509145","NCT05909618","Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","14","Cohort 1 (MBM) Inclusion Criteria\n\n1. Age ≥ 18 years.\n2. Estimated life expectancy at least 3 months\n3. Have metastatic melanoma with primarily diagnosed or newly progressing brain metastases.\n4. Was treated with 1 prior systemic line of immunotherapy - either PD-1 inhibitor monotherapy or combined CTLA4 and PD-1 antibodies or another investigational combination of immunotherapy. Patients with BRAF-mutant melanoma who have also received BRAF mutation targeted therapy are also eligible.\n5. Have failed prior immunotherapy line, either due to primary resistance or acquired resistance.\n6. Have measurable disease defined by RECIST criteria and have at least one, non-previously irradiated brain metastasis of at least 1-cm short diameter. Otherwise, previously irradiated lesions should present with enlargement following radiation therapy.\n7. Is clinically stable with no neurological deficits. Patients may receive steroid supportive therapy up to 10 mg of prednisone or the equivalent.\n8. Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n9. Adequate organ function defined by blood tests for blood count and chemistry.\n10. Women of childbearing potential practicing an acceptable method of birth control.\n11. Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.\n\n    Exclusion Criteria\n12. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 10 mg prednisone will be allowed\n13. Have leptomeningeal spread.\n14. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.\n15. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.\n16. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.\n17. Previous or current brain hemorrhage.\n18. The patient had, or is expected to undergo, allogeneic hematopoietic stem cell transplantation (HSCT).\n19. The patient had a contraindication for undergoing brain MRI.\n20. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n21. Pregnant or lactating\n22. Treatment with other investigational drugs within \\\u003C21 days of start of day 1 of the study treatment.\n23. Any contraindication for treatment with nivolumab according to the product's labels.\n\nCohort 2 (Recurrent or Progressive GB) Inclusion Criteria\n\n1. Age ≥ 18 years.\n2. Estimated life expectancy at least 3 months\n3. Have with recurrent or persistent GB\n4. Received first line therapy with brain irradiation and maintenance temozolamide.\n5. Measurable disease per RANO criteria on brain MRI.\n6. Have Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2.\n7. Adequate organ function defined by blood tests for blood count and chemistry.\n8. Women of childbearing potential practicing an acceptable method of birth control.\n9. Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.\n\nExclusion Criteria\n\n1. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed\n2. Have leptomeningeal spread.\n3. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.\n4. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.\n5. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.\n6. Previous or current brain hemorrhage.\n7. The patient had, or is expected to undergo, allogeneic HSCT.\n8. The patient had a contraindication for undergoing brain MRI.\n9. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n10. Pregnant or lactating\n11. Treatment with other investigational drugs within \\\u003C21 days of start of day 1 of the study treatment.\n12. Any contraindication for treatment with nivolumab according to the product's labels.\n\nCohort 3 (Newly Diagnosed Unmethylated GB) Inclusion Criteria\n\n1. Age ≥ 18 years.\n2. Estimated life expectancy at least 3 months.\n3. Histologically confirmed newly diagnosed GB.\n4. Tumor test result shows MGMT unmethylated type.\n5. Received definitive brain irradiation.\n6. Patients may be treated with novo TTF (optune) per local standard.\n7. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n8. Adequate organ function defined by blood tests for blood count and chemistry.\n9. Women of childbearing potential practicing an acceptable method of birth control.\n10. Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.\n\nExclusion Criteria\n\n1. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed\n2. Have leptomeningeal spread.\n3. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.\n4. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.\n5. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.\n6. Previous or current brain hemorrhage.\n7. The patient had, or is expected to undergo, allogeneic HSCT.\n8. The patient had a contraindication for undergoing brain MRI.\n9. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n10. Be pregnant or lactating\n11. Treatment with other investigational drugs within \\\u003C21 days of start of day 1 of the study treatment.\n\nAny contraindication for treatment with nivolumab according to the product's labels",{"count":572,"type":20},33,[195],"A single-center, open-label, non-randomized phase I\u002FII study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB.\n\nSubjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts:\n\nCohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy.\n\nCohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment.\n\nCohort 3: Patients with newly diagnosed GB who were evaluated for methylguanine-DNA methyltransferase(MGMT) methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.",[576,577,578],"Advanced Glioblastoma","Metastatic Melanoma in the Central Nervous System","MGMT-Unmethylated Glioblastoma","2025-07-17",{"date":581,"type":32},"2025-07-22",{"date":583,"type":32},"2023-07-11",{"date":585,"type":20},"2030-07-30",{"name":38,"class":39},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":53,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":40},"100585832","paromomycin-or-metronidazole-for-symptomatic-dientamoeba-fragilis-in-adults-100585832","NCT06907498","Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults","Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults (COMFORTER Trial) - Protocol for a Superiority Double Blind, Randomized Controlled Trial","COMFORTER","Inclusion Criteria:\n\nPatients over the age of 18, not including pregnant women - With persistent gastrointestinal symptoms (over one month).\n\n* Without any other clear diagnosis to explain these symptoms according to medical records.\n* With a positive PCR stool test for D. fragilis without any additional pathogen (patients with Blastocystis hominis in feces will not be excluded).\n\nExclusion Criteria:\n\n* Pregnancy\n* Hypersensitivity to any of the study drugs or to aminoglycosides\n* Patients age below 18 years\n* Metronidazole or paromomycin treatment in the last 3 months",{"count":525,"type":20},[55],"Dientameba Fragilis (D.fragilis) is a protozoan found in the digestive tract - in the human colon. there are disagreements regarding the preferred treatment for these cases, with several regimens tested in mostly small observational studies. Several drugs are currently recommended for D.fragilis, with metronidazole most commonly used. However, metronidazole therapy for treating dientamoebiasis in children was not associated with better clinical outcomes in a randomized, double-blinded and placebo-controlled clinical trial.\n\nHence, we aim to perform a double blind, randomized controlled trial, evaluating the clinical and microbiological efficacy of paromomycin versus metronidazole for the treatment of symptomatic adults with PCR positive dientamoeba fragilis.\n\nThe primary outcomes would be clinical improvement or resolution. Secondary outcomes include clinical improvement evaluated by a visual analogue scale; microbiological eradication, quality of life, and adverse events related to therapy.\n\nWe plan to include 60 patients (30 per arm)",[599],"Dientamoeba Fragilis Infection",[601,602,603,604,605],"Dientamoeba Fragilis","Diarrhea","Paromomycin","Metronidazole","Treatment","2025-03-26",{"date":608,"type":32},"2025-04-02",{"date":610,"type":32},"2024-01-22",{"date":612,"type":20},"2026-12",{"name":38,"class":39},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":4},"100568850","the-utility-of-hand-held-ultrasound-devices-to-detect-bowel-wall-inflammatory-activity-in-crohns-disease-100568850","NCT06686589","The Utility of Hand-held Ultrasound Devices to Detect Bowel Wall Inflammatory Activity in Crohn's Disease","Inclusion Criteria:\n\nCrohn disease of the terminal ileum and colon- Age\\> 18\n\nExclusion Criteria:\n\n* Pregnancy Inability to visualize he bowel on US Proximal Crohn's disease Proctitis",{"count":218,"type":20},"One of the major obstacles in implementing intestinal ultrasound services for inflammatory bowel disease (IBD) patients relates to the costs of acquiring ultrasound (US) machines. The costs of high-end (and higher levels of quality) US machines are considerable, and although large medical centers in developed countries can obtain US machines, smaller centers in rural areas, community centers and centers in undeveloped countries may struggle with the cost of the machines. The lack of availability of point-of-care intestinal ultrasound impedes the medical treatment IBD patients receive. Recently, new models of hand-held small ultrasound machines were introduced to the market by large ultrasound companies. These machines are affordable and are used mainly for point-of-care ultrasound exams. We hypothesize that if the image quality acquired by these machines is proven to be good enough for the detection of bowel inflammation and complications in Crohn's disease (CD) patients, the use of intestinal ultrasound can potentially increase, allowing better care for CD patients.\n\nOur idea is to compare the accuracy of various hand-held ultrasound devices to detect ultrasonographic signs of bowel inflammatory activity (especially increased bowel wall thickness) to that of high-end and premium US machines. The first part of the project will include examining the quality of 2 different hand-held US machines (GE VSCAN air and Philips Lumify) by 3 experienced ultra-sonographers. If the achieved level of accuracy for the detection of bowel wall inflammatory activity will be sufficient (AUC\\>0.8), we aim to move to the second part of the project. This step focuses on hand-held US machines by gastroenterologists with various levels of IUS experience. Therefore, we aim to examine the accuracy of hand-held US machines for the detection of inflammatory activity by delivering the hand-held US machines to 10 GI specialists who completed the IBUS educational curriculum for IUS (at least module 1+2) with various levels of IUS expertise.\n\n* Project Goal 1) To examine the capability and accuracy of hand-held ultrasound machines to detect bowel wall inflammatory activity and complications in CD patients.\n* Strategy - Comparing various ultrasonographic signs of inflammation acquired by hand-held US machines to that acquired by high-end and premium US machines.\n* Outcomes - Accuracy of hand-held ultrasound machines in the detection of bowel wall inflammatory activity The problem being addressed by the proposed project - Dissemination of IUS is limited due to the high costs of US machines. The use of affordable hand-held US machines for the detection of inflammatory activity will expand the IUS incorporation into the CD diagnosis, monitoring, and treatment approaches, improving patient outcomes.\n\nSignificance\u002FImpact The use of affordable and precise US machines will disseminate the use of IUS and expand the IUS incorporation into the diagnosis, monitoring, and treatment of CD, improving patient outcomes",[623],"Crohn Disease (CD)",[625,626,627],"Crohn disease","intestinal ultrasound","hand held ultrasound","2024-11-12",{"date":630,"type":32},"2024-11-13",{"date":632,"type":20},"2025-01-01",{"date":134,"type":20},{"name":38,"class":39},""]